# Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer

> **NCT00253370** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 44 (actual)

## Conditions studied

- Adenocarcinoma of the Gastroesophageal Junction
- Metastatic Gastric Cancer
- Advanced Unresectable Gastric Cancer

## Interventions

- **DRUG:** BAY 43-9006
- **DRUG:** docetaxel
- **DRUG:** cisplatin

## Key facts

- **NCT ID:** NCT00253370
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2008-05
- **Final completion:** 2010-09
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2014-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00253370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00253370, "Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00253370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*